MedTrace Logo

Antibacterial Effect of Zinc Oxide Nanoparticles on Acinetobacter Baumannii Isolated from Patients with Hospital Acquired Infections in Sohag University Hospitals, Egypt

NCT06628076 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2024-10-04

No results posted yet for this study

Summary

A. baumannii is known as the most frequently isolated organism in intensive care units (ICUs), causing a variety of nosocomial infections, including pneumonia, urinary tract infections (UTIs), bacteremia as well as skin and soft tissue infections. These infections are usually associated with high mortality rates ranging between 26% among hospitalized patients and 43% among ICU patients.

Conditions

  • Infections, Nosocomial
  • Infections, Respiratory Tract

Interventions

DIAGNOSTIC_TEST

Culture specific antibiotic therapy

Samples will be cultured on MacConkey agar. Morphological identifications of growth isolates by Gram staining, colony features and conventional biochemical tests. All isolates will be identified to species level using automated bacterial identification systems.

DIAGNOSTIC_TEST

Antibiotic

Strains confirmed as A. baumannii will be examined for their different antibiotic susceptibility by modified Kirby Bauer\'s disc diffusion method on Mueller Hinton Agar.

DIAGNOSTIC_TEST

Biofilm assessment

The biofilm formation activity of A. baumannii isolates will be tested using the microtitre plate technique

DIAGNOSTIC_TEST

nanoparticle zinc oxide

Detection of the effect of ZnO NPs on the biofilm producer MDR A. baumannii strains using the same method

DIAGNOSTIC_TEST

Molecular detection of antibiotic resistance

\- Evaluation the effect of ZnO NPs on the expression of some efflux pump genes, and biofilm related genes in MDR A. baumannii isolates using Real time PCR technology.

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Eligibility

Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-10
Primary Completion
2024-10-10
Completion
2025-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06628076 on ClinicalTrials.gov